DC260126, a small-molecule antagonist of GPR40.

≥98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

DC 260126；DC-260126

white to beige powder

DMSO : ≥ 100 mg/mL (325.33 mM)

DC260126 is a small-molecule antagonist of GPR40 that protects against pancreatic β-cells dysfunction in db/db mice. After giving different dose of DC260126 to nine-week-old db/db mice for 5 days, the fasting serum insulin (FSI) level is decreased dose-dependently. And both 10 mg/kg and 30 mg/kg body weight can reduce FSI level of db/db mice significantly. DC260126, a small-molecule antagonist of GPR40, is evaluated the effect of on glucose and lipid metabolism in obese Zucker rats. Rats are treated intraperitoneally with 6 mg/kg of DC260126 for 8 weeks. DC260126 treatment significantly decreases serum insulin levels by about 20% (147.5±10.42 versus 182.36±7.22, p<0.05). DC260126 treatment causes an elevation of body weight gain from 3 to 6 weeks compared with the vehicle-treated group. Compared with the vehicle-treated group, DC260126 treatment induces a significant increase of Akt phosphorylation levels in liver as assessed by western blotting.